Overview
Vericel Q3 revenue of $67.5 mln beats analyst expectations
MACI revenue grows 25% to $55.7 mln, driving overall revenue growth
Net income for Q3 at $5.1 mln, compared to a loss last year
Outlook
Vericel projects full-year revenue of $272 to $276 mln
Company reaffirms MACI revenue growth in low 20% range
Vericel maintains full-year gross margin guidance at 74%
MACI sales force expansion on track for completion in Q4, supporting future growth
Result Drivers
MACI REVENUE GROWTH - MACI revenue increased by 25% to $55.7 mln, contributing significantly to overall revenue growth
NEXOBRID REVENUE GROWTH - NexoBrid revenue grew 38% year-over-year and 26% quarter-over-quarter, marking a record quarter
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $67.50 mln | $64.60 mln (8 Analysts) |
Q3 EPS | $0.10 | ||
Q3 Net Income | $5.07 mln | ||
Q3 Adjusted EBITDA | $17 mln | ||
Q3 Gross Margin | 73.50% | ||
Q3 Adjusted EBITDA Margin | 25.00% | ||
Q3 Gross Profit | $49.59 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vericel Corp is $55.00, about 32.4% above its November 5 closing price of $37.20
The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 70 three months ago
Press Release: ID:nGNX5tDGzT
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)